The "Diabetic Foot Ulcer - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the DFU, historical and forecasted epidemiology as well as the DFU market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
The DFU market report provides current treatment practices, emerging drugs, DFU market share of the individual therapies, current and forecasted DFU market size from 2018 to 2030 segmented by seven major markets. The Report also covers current DFU treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
The main goal in the management of diabetic ulcers is the closure of the wound. Treatment of DFU wound in DM patients is carried out regularly with the type of action depending on the severity of the ulcer and the presence or absence of ischemia. The basis of DFU therapy is: necrotomy/debridement, reducing the load/pressure on the area of the injury (off-loading), manage the infection by diagnosing the type of bacteria, providing adequate antibiotics and ulcer treatment using wound dressing clean and moist.
The DFU epidemiology division provides insights about historical and current DFU patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Country Wise- DFU Epidemiology
In the United States, the total number of prevalent cases of DFU was 4,551,498 cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.
In the year 2020, the total prevalent cases of DFU were 1,274,933 cases in EU-5 which are expected to grow during the study period, i.e., 2018-2030.
In Japan, the total number of prevalent cases of DFU was 168,547 cases in the year 2020 which are expected to grow during the study period, i.e., 2018-2030.
DFU Market Outlook
DFU is one of the most significant and devastating complications of poorly controlled diabetes (type 1 and type 2), and probably the major component of the diabetic foot. In most DFU patients, peripheral neuropathy and peripheral arterial disease (PAD) (or both) play a central role and people who develop foot ulcers lose the ability to feel pain in the affected area. DFUs are thus complex, chronic wounds, which have a major long-term impact on the morbidity, mortality, and quality of patients' lives. The goals of therapy for patients with DFU are wound closure, eradication of clinical evidence of infection, and the avoidance of soft tissue loss and amputations.
Currently, treatment strategies for DFU mainly include non-surgical treatment for mild and moderate ulcers and surgical treatment for ulcers classified as severe. Non-surgical treatment options mainly include simple daily wound care, using growth factors and skin substitutes for wound repair, antibiotics for the deep infection, drainage, and cellulitis. Whereas, surgical treatment options mainly include debridement, or removal of unhealthy tissue, and vascular surgeries, to induce better blood flow. The development of growth factor for treatment represents an important therapeutic advance for diabetic neuropathic foot ulcers with adequate blood supply.
In the coming years, the DFU market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence DFU R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
Major players are involved in developing therapies for DFU. The launch of emerging therapies will significantly impact the DFU market.
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for DFU.
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ygqn1o
View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005476/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900